Headquartered in Winston-salem, NC Fiscal year ends December NASDAQ: PROK prokidney.com
ProKidney Corp. is a late clinical-stage biotechnology company developing cell therapies for chronic kidney disease (CKD). It was founded in 2015 after a decade of research.
Its lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy (RMAT) designation. Rilparencel is delivered through up to two minimally invasive percutaneous injections, one in each kidney.
It is being evaluated in the Phase 3 REGEN-006 (PROACT 1) randomized, blinded, sham-controlled trial in patients with Stage 4 and late Stage 3b CKD with type 2 diabetes and albuminuria. The company estimates this population includes over one million people in the U.S. The trial is designed to support potential accelerated approval based on an eGFR slope surrogate endpoint, with a composite time-to-event confirmatory endpoint.
ProKidney generates minimal revenue and funds operations from its cash and marketable securities. Its Class A common stock trades on Nasdaq under PROK, and it has an Up-C structure with Class B shares and a redeemable noncontrolling interest. Updated
The wider loss is the cost of racing to a readout: R&D jumped to $40.8 million from $26.8 million as PROACT 1 enrollment expanded past 500 patients. Cash of $141.9 million funds operations only into mid-2027, right when the pivotal eGFR slope data land in Q2 2027.
ProKidney Corp. is a late clinical-stage biotechnology company developing cell therapies for chronic kidney disease (CKD). It was founded in 2015 after a decade of research.
The Wall Street consensus 12-month price target for PROK is $7.88.